Titre : Inhibiteur tissulaire de métalloprotéinase-1

Inhibiteur tissulaire de métalloprotéinase-1 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Attention Deficit Disorder with Hyperactivity
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Inhibiteur tissulaire de métalloprotéinase-1 : Questions médicales les plus fréquentes", "headline": "Inhibiteur tissulaire de métalloprotéinase-1 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Inhibiteur tissulaire de métalloprotéinase-1 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-08", "dateModified": "2025-04-03", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Inhibiteur tissulaire de métalloprotéinase-1" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Inhibiteur tissulaire des métalloprotéinases", "url": "https://questionsmedicales.fr/mesh/D019714", "about": { "@type": "MedicalCondition", "name": "Inhibiteur tissulaire des métalloprotéinases", "code": { "@type": "MedicalCode", "code": "D019714", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.815.875" } } }, "about": { "@type": "MedicalCondition", "name": "Inhibiteur tissulaire de métalloprotéinase-1", "alternateName": "Tissue Inhibitor of Metalloproteinase-1", "code": { "@type": "MedicalCode", "code": "D019715", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Anna Pryczynicz", "url": "https://questionsmedicales.fr/author/Anna%20Pryczynicz", "affiliation": { "@type": "Organization", "name": "Department of Pathomorphology, Medical University of Bialystok, Bialystok, Poland." } }, { "@type": "Person", "name": "Adina Elena Stanciu", "url": "https://questionsmedicales.fr/author/Adina%20Elena%20Stanciu", "affiliation": { "@type": "Organization", "name": "Department of Carcinogenesis and Molecular Biology, 'Prof. Dr. Alexandru Trestioreanu' Institute of Oncology, 022328 Bucharest, Romania." } }, { "@type": "Person", "name": "Adina Zamfir-Chiru-Anton", "url": "https://questionsmedicales.fr/author/Adina%20Zamfir-Chiru-Anton", "affiliation": { "@type": "Organization", "name": "ENT Department, 'Grigore Alexandrescu' Children's Emergency Hospital, 011743 Bucharest, Romania." } }, { "@type": "Person", "name": "Marcel Marian Stanciu", "url": "https://questionsmedicales.fr/author/Marcel%20Marian%20Stanciu", "affiliation": { "@type": "Organization", "name": "Electrical Engineering Faculty, 'Politehnica' University, 060042 Bucharest, Romania." } }, { "@type": "Person", "name": "Mirela Gherghe", "url": "https://questionsmedicales.fr/author/Mirela%20Gherghe", "affiliation": { "@type": "Organization", "name": "Department of Nuclear Medicine, 'Prof. Dr. Alexandru Trestioreanu' Institute of Oncology, 022328 Bucharest, Romania." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).", "datePublished": "2023-03-27", "url": "https://questionsmedicales.fr/article/36971690", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/14651858.CD009885.pub3" } }, { "@type": "ScholarlyArticle", "name": "Altered somatosensory processing in adult attention deficit hyperactivity disorder.", "datePublished": "2024-08-13", "url": "https://questionsmedicales.fr/article/39138461", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12888-024-06002-9" } }, { "@type": "ScholarlyArticle", "name": "Parental perspectives on attention-deficit/hyperactivity disorder treatments for children.", "datePublished": "2022-06-13", "url": "https://questionsmedicales.fr/article/35695509", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1177/13591045221108836" } }, { "@type": "ScholarlyArticle", "name": "Potential Inflammatory Biomarker in Patients with Attention Deficit Hyperactivity Disorder.", "datePublished": "2022-10-27", "url": "https://questionsmedicales.fr/article/36361835", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijms232113054" } }, { "@type": "ScholarlyArticle", "name": "Sensory Processing in Children and Adolescents with Attention Deficit Hyperactivity Disorder.", "datePublished": "2022-10-14", "url": "https://questionsmedicales.fr/article/36239408", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1177/10870547221129306" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines sécrétoires inhibitrices de protéinases", "item": "https://questionsmedicales.fr/mesh/D053491" }, { "@type": "ListItem", "position": 5, "name": "Inhibiteur tissulaire des métalloprotéinases", "item": "https://questionsmedicales.fr/mesh/D019714" }, { "@type": "ListItem", "position": 6, "name": "Inhibiteur tissulaire de métalloprotéinase-1", "item": "https://questionsmedicales.fr/mesh/D019715" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Inhibiteur tissulaire de métalloprotéinase-1 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Inhibiteur tissulaire de métalloprotéinase-1", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-11", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Inhibiteur tissulaire de métalloprotéinase-1", "description": "Comment diagnostiquer une anomalie de TIMP-1 ?\nQuels symptômes indiquent un déséquilibre de TIMP-1 ?\nY a-t-il des biomarqueurs associés à TIMP-1 ?\nQuel rôle joue TIMP-1 dans le cancer ?\nComment TIMP-1 est-il mesuré en clinique ?", "url": "https://questionsmedicales.fr/mesh/D019715?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Inhibiteur tissulaire de métalloprotéinase-1", "description": "Quels symptômes sont liés à une surproduction de TIMP-1 ?\nTIMP-1 affecte-t-il la cicatrisation des plaies ?\nQuels signes indiquent une carence en TIMP-1 ?\nY a-t-il des symptômes associés à des maladies inflammatoires ?\nComment TIMP-1 influence-t-il l'inflammation ?", "url": "https://questionsmedicales.fr/mesh/D019715?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Inhibiteur tissulaire de métalloprotéinase-1", "description": "Peut-on prévenir les déséquilibres de TIMP-1 ?\nQuels facteurs de mode de vie influencent TIMP-1 ?\nY a-t-il des recommandations pour maintenir TIMP-1 ?\nLes suppléments peuvent-ils aider TIMP-1 ?\nComment le suivi médical aide-t-il TIMP-1 ?", "url": "https://questionsmedicales.fr/mesh/D019715?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Inhibiteur tissulaire de métalloprotéinase-1", "description": "Quels traitements ciblent TIMP-1 ?\nTIMP-1 peut-il être utilisé comme cible thérapeutique ?\nQuels médicaments influencent TIMP-1 ?\nY a-t-il des essais cliniques sur TIMP-1 ?\nComment les traitements affectent-ils TIMP-1 ?", "url": "https://questionsmedicales.fr/mesh/D019715?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Inhibiteur tissulaire de métalloprotéinase-1", "description": "Quelles complications peuvent survenir avec un excès de TIMP-1 ?\nTIMP-1 est-il lié à des maladies chroniques ?\nComment TIMP-1 affecte-t-il la santé cardiovasculaire ?\nY a-t-il des risques de cancer liés à TIMP-1 ?\nQuels effets secondaires peuvent résulter d'un traitement de TIMP-1 ?", "url": "https://questionsmedicales.fr/mesh/D019715?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Inhibiteur tissulaire de métalloprotéinase-1", "description": "Quels facteurs augmentent le risque de déséquilibre de TIMP-1 ?\nLes maladies auto-immunes influencent-elles TIMP-1 ?\nLe stress a-t-il un impact sur TIMP-1 ?\nL'alimentation joue-t-elle un rôle dans TIMP-1 ?\nY a-t-il un lien entre TIMP-1 et l'inactivité physique ?", "url": "https://questionsmedicales.fr/mesh/D019715?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie de TIMP-1 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins mesurant les niveaux de TIMP-1 peuvent être effectués." } }, { "@type": "Question", "name": "Quels symptômes indiquent un déséquilibre de TIMP-1 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme l'inflammation ou des troubles de cicatrisation peuvent survenir." } }, { "@type": "Question", "name": "Y a-t-il des biomarqueurs associés à TIMP-1 ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des biomarqueurs comme le collagène et les métalloprotéinases sont souvent étudiés." } }, { "@type": "Question", "name": "Quel rôle joue TIMP-1 dans le cancer ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "TIMP-1 peut inhiber la progression tumorale en régulant la dégradation de la matrice." } }, { "@type": "Question", "name": "Comment TIMP-1 est-il mesuré en clinique ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Il est mesuré par des tests immunologiques spécifiques dans des échantillons de sang." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une surproduction de TIMP-1 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Une surproduction peut entraîner des douleurs articulaires et une fibrose tissulaire." } }, { "@type": "Question", "name": "TIMP-1 affecte-t-il la cicatrisation des plaies ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un excès de TIMP-1 peut ralentir la cicatrisation des plaies." } }, { "@type": "Question", "name": "Quels signes indiquent une carence en TIMP-1 ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Une carence peut se manifester par une dégradation excessive de la matrice extracellulaire." } }, { "@type": "Question", "name": "Y a-t-il des symptômes associés à des maladies inflammatoires ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des maladies comme l'arthrite peuvent être liées à des niveaux anormaux de TIMP-1." } }, { "@type": "Question", "name": "Comment TIMP-1 influence-t-il l'inflammation ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "TIMP-1 peut moduler l'inflammation en régulant les métalloprotéinases impliquées." } }, { "@type": "Question", "name": "Peut-on prévenir les déséquilibres de TIMP-1 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et un mode de vie sain peuvent aider à maintenir l'équilibre." } }, { "@type": "Question", "name": "Quels facteurs de mode de vie influencent TIMP-1 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Le tabagisme et l'obésité peuvent affecter les niveaux de TIMP-1." } }, { "@type": "Question", "name": "Y a-t-il des recommandations pour maintenir TIMP-1 ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Pratiquer une activité physique régulière et gérer le stress sont recommandés." } }, { "@type": "Question", "name": "Les suppléments peuvent-ils aider TIMP-1 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Certains suppléments antioxydants peuvent soutenir la régulation de TIMP-1." } }, { "@type": "Question", "name": "Comment le suivi médical aide-t-il TIMP-1 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi régulier permet de détecter et de corriger les déséquilibres de TIMP-1." } }, { "@type": "Question", "name": "Quels traitements ciblent TIMP-1 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies géniques et des inhibiteurs spécifiques sont en cours d'étude." } }, { "@type": "Question", "name": "TIMP-1 peut-il être utilisé comme cible thérapeutique ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en régulant TIMP-1, on peut potentiellement traiter certaines pathologies." } }, { "@type": "Question", "name": "Quels médicaments influencent TIMP-1 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Certains anti-inflammatoires peuvent moduler l'expression de TIMP-1." } }, { "@type": "Question", "name": "Y a-t-il des essais cliniques sur TIMP-1 ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, plusieurs essais cliniques explorent son rôle dans diverses maladies." } }, { "@type": "Question", "name": "Comment les traitements affectent-ils TIMP-1 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements peuvent soit augmenter, soit diminuer les niveaux de TIMP-1 selon le contexte." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec un excès de TIMP-1 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Un excès peut entraîner des maladies fibrosantes et des troubles cardiovasculaires." } }, { "@type": "Question", "name": "TIMP-1 est-il lié à des maladies chroniques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux anormaux de TIMP-1 sont associés à des maladies chroniques comme le diabète." } }, { "@type": "Question", "name": "Comment TIMP-1 affecte-t-il la santé cardiovasculaire ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés de TIMP-1 peuvent contribuer à l'athérosclérose." } }, { "@type": "Question", "name": "Y a-t-il des risques de cancer liés à TIMP-1 ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés de TIMP-1 peuvent être associés à une progression tumorale." } }, { "@type": "Question", "name": "Quels effets secondaires peuvent résulter d'un traitement de TIMP-1 ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements peuvent entraîner des effets secondaires comme des réactions allergiques." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de déséquilibre de TIMP-1 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'âge avancé, le tabagisme et l'obésité sont des facteurs de risque connus." } }, { "@type": "Question", "name": "Les maladies auto-immunes influencent-elles TIMP-1 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les maladies auto-immunes peuvent perturber l'équilibre de TIMP-1." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur TIMP-1 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut affecter les niveaux de TIMP-1 dans l'organisme." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle dans TIMP-1 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en graisses saturées peut perturber les niveaux de TIMP-1." } }, { "@type": "Question", "name": "Y a-t-il un lien entre TIMP-1 et l'inactivité physique ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'inactivité physique peut contribuer à des déséquilibres de TIMP-1." } } ] } ] }

Sources (10000 au total)

Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed and treated psychiatric disorders in childhood. Typically, children and adolescents with ADHD find it difficult to... To assess the beneficial and harmful effects of methylphenidate for children and adolescents with ADHD.... We searched CENTRAL, MEDLINE, Embase, three other databases and two trials registers up to March 2022. In addition, we checked reference lists and requested published and unpublished data from manufac... We included all randomised clinical trials (RCTs) comparing methylphenidate versus placebo or no intervention in children and adolescents aged 18 years and younger with a diagnosis of ADHD. The search... Two review authors independently conducted data extraction and risk of bias assessment for each trial. Six review authors including two review authors from the original publication participated in the... We included 212 trials (16,302 participants randomised); 55 parallel-group trials (8104 participants randomised), and 156 cross-over trials (8033 participants randomised) as well as one trial with a p... methylphenidate versus placebo or no intervention may improve teacher-rated ADHD symptoms (standardised mean difference (SMD) -0.74, 95% confidence interval (CI) -0.88 to -0.61; I² = 38%; 21 trials; 1... methylphenidate may cause more adverse events considered non-serious versus placebo or no intervention (RR 1.23, 95% CI 1.11 to 1.37; I² = 72%; 35 trials 5342 participants; very low-certainty evidence... The majority of our conclusions from the 2015 version of this review still apply. Our updated meta-analyses suggest that methylphenidate versus placebo or no-intervention may improve teacher-rated ADH...

Altered somatosensory processing in adult attention deficit hyperactivity disorder.

Tactile sensitivity and sensory overload in ADHD are well-documented in clinical-, self-, and parent- reports, but empirical evidence is scarce and ambiguous and focuses primarily on children. Here, w... Somatosensory evoked potential (SEP) amplitudes were measured in 27 adults with ADHD and 24 controls during four conditions (rest, stroking of the own arm, stroking of the arm by a researcher, and str... Participants with ADHD self-reported greater tactile sensitivity and ADHD symptom severity than controls and received higher scores on the Qb-test. These values correlated with one another. ADHD parti... We find that ADHD symptomatology and touch sensitivity are directly linked, using both self-reports and experimental measures. We also find evidence of tactile sensory overload in ADHD, and an indicat...

Sensory Processing in Children and Adolescents with Attention Deficit Hyperactivity Disorder.

The aim is to assess the sensory processing difficulties in children and adolescents with ADHD.... In all, 38 ADHD children of the age group 6-14 years and 34 age- and gender-matched typically developing controls were included in the study. Sensory processing was assessed on Child Sensory Profile-2... A significantly higher sensory processing difficulties were seen in children with ADHD than typically developing controls. There were positive correlations between the scores of Child sensory profile ... Sensory problems were common in children with ADHD and add to the functional impairments....

Preterm postnatal complications and risk of attention-deficit/hyperactivity disorder.

To investigate the association between the risk of attention-deficit/hyperactivity disorder (ADHD) and preterm birth and determine how postnatal complications in children born preterm is associated wi... This population-based cohort study used data from the Hong Kong electronic medical records. We followed 359 614 children (48% female; 6-17 years old, mean 11 years 7 months, SD 3 years 2 months) born ... The risk of ADHD was 4.0% in children born at term and 5.1% in children born preterm. The odds ratio for ADHD was 2.08 (95% confidence interval [CI] 1.64-2.64) for children born extremely preterm, 1.6... Children born preterm in all subcategories, from extremely preterm to late preterm, have increased risk of ADHD. Early respiratory infection partially mediates the risk of ADHD in children born preter...

Effect of Past Pharmacotherapy for Attention-Deficit/Hyperactivity Disorder on Substance Use Disorder.

Substance use disorders (SUDs) are a considerable public health problem. Attention-deficit/hyperactivity disorder (ADHD) frequently occurs in patients with SUD. Several studies demonstrated that ADHD ... The study aimed to explore the effect of childhood ADHD pharmacotherapy on later life's functional impairment and substance use patterns.... Treatment-seeking SUD patients with ADHD (n = 52) were recruited from various rehabilitation facilities in South Africa. Adult ADHD individuals without SUD (n = 48) were recruited from clinicians, ret... Medicated participants (n = 59) showed lower levels of ADHD-related impairment across all functional domains (p < 0.001), compared to non-medicated participants (n = 41). They also consumed less alcoh... Childhood ADHD pharmacotherapy might be associated with a decreased risk for substance use in adulthood and lower ADHD-related impairment. Despite study limitations, these findings underline the impor...